Literature DB >> 8476721

Masking of physicians in the Growth Failure in Children with Renal Diseases Clinical Trial.

R M Boyle1, V M Chinchilli, D A Shasky.   

Abstract

Masking--hiding identities of treatments from the patient, physician and/or statistician--is a critical element in clinical trials. Wherever possible, masking is implemented to eliminate observational bias or systematic error. In this paper, general concepts of masking in clinical trials are examined. Specific masking procedures used in the "Growth Failure in Children with Renal Diseases" (GFRD) Clinical Trial are described. A method to evaluate the "success" of this masking procedure for physicians is introduced. For each randomized patient at each clinical center, the clinic director was asked to predict which treatment (1,25-dihydroxyvitamin D3 or dihydrotachysterol) was assigned. Results showed that 72% of responses initially indicated "absolutely no idea" of treatment. Additional analyses revealed that the number and percentage of "correct" guesses were essentially equal for the two treatment groups and that a patient's time on treatment did not affect the mask. We conclude that the mask of physicians in the GFRD Clinical Trial was well maintained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476721     DOI: 10.1007/bf00864403

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Ascorbic acid for the common cold. A prophylactic and therapeutic trial.

Authors:  T R Karlowski; T C Chalmers; L D Frenkel; A Z Kapikian; T L Lewis; J M Lynch
Journal:  JAMA       Date:  1975-03-10       Impact factor: 56.272

2.  History and organization of the Growth Failure in Children with Renal Diseases Study.

Authors:  J C Chan; P T McEnery; B H Brouhard; V M Chinchilli; I Greifer
Journal:  J Pediatr       Date:  1990-02       Impact factor: 4.406

3.  Protocol of the Growth Failure in Children with Renal Diseases Study.

Authors:  J C Chan; P T McEnery; V M Chinchilli; R M Boyle; M D Massie; S S Jennings; E C Kohaut; I G Dresner; A Tejani; G S Arbus
Journal:  J Pediatr       Date:  1990-02       Impact factor: 4.406

Review 4.  Rationale of the Growth Failure in Children with Renal Diseases Study.

Authors:  J C Chan; I Greifer; F G Boineau; S A Mendoza; P T McEnery; C F Strife; C L Abitbol; F B Stapleton; S Roy; J Strauss
Journal:  J Pediatr       Date:  1990-02       Impact factor: 4.406

5.  The Coronary Drug Project. Closing down the study.

Authors:  W F Krol
Journal:  Control Clin Trials       Date:  1983-12

6.  Assessment of double-blindness at the conclusion of the beta-Blocker Heart Attack Trial.

Authors:  R P Byington; J D Curb; M E Mattson
Journal:  JAMA       Date:  1985 Mar 22-29       Impact factor: 56.272

7.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

  7 in total
  1 in total

Review 1.  Interventions for metabolic bone disease in children with chronic kidney disease.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-11-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.